Vizimpro
Chemical Name | dacomitinib |
Dosage Form | Tablet (oral; 15 mg, 30 mg, 45 mg) |
Drug Class | Kinase inhibitors |
System | Respiratory |
Company | Pfizer |
Approval Year | 2018 |
Indication
- Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test